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a b s t r a c t
Forty years ago, non-steroidal anti-inflammatory drugs were first reported to decrease
systemic prostaglandin levels and promote ductus arteriosus (DA) closure. And yet,
prolonged patency of the DA (PDA) remains a significant clinical problem, complicated by
imperfect therapies and wide variations in treatment strategy. There are few pharmacology-
based tools available for treating PDA (indomethacin, ibuprofen, and acetaminophen), or for
maintaining DA patency (PGE1) as is needed to facilitate corrective surgery for ductus-
dependent congenital heart defects. Unfortunately, all of these treatments are inefficient and
are associated with concerning adverse effects. This review highlights novel potential DA
drug targets that may expand our therapeutic repertoire beyond the prostaglandin pathway.
& 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
The ductus arteriosus (DA) is a muscular artery that connects
the fetal aorta and pulmonary artery, providing an integral
shunt of the fetal circulation, essential for maintaining fetal
wellbeing. In utero, the DA diverts approximately 90% of the
right ventricular output away from the high-resistance pul-
monary circulation and into the systemic umbilical-placental
circulation where gas exchange can occur with maternal
blood.1 Postnatally, the DA normally closes within 72 hours
after birth to facilitate perfusion of the newly-inflated lungs.
Failure to close results in a persistent left-to-right shunt
termed patent ductus arteriosus (PDA). PDA affects up to
80% of premature infants2 and accounts for 5–10% of all
congenital heart defects in term infants.3 Hemodynamically
significant PDA is associated with significant morbidities
including neurodevelopmental impairment, intraventricular
hemorrhage, pulmonary hemorrhage, respiratory distress
syndrome, bronchopulmonary dysplasia, necrotizing enter-
ocolitis (NEC), spontaneous intestinal perforation, and
congestive heart failure.4 On the other hand, in ductus-
dependent heart lesions, which account for 20–25% of
all congenital heart defects, it is necessary that patency
of the neonatal DA be maintained in order to preserve
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life-saving pulmonary or systemic circulation prior to correc-
tive surgery.5
The fetal DA has intrinsic tone and requires dilating factors
to maintain its patency in utero. Nitric oxide (NO) and
prostaglandin E2 (PGE2) induce vessel relaxation by activating
cGMP/PKG and cAMP/PKA signaling, respectively. While NO
and PGE2 are typically considered primary mediators of DA
dilation, other factors, including potassium (Kþ) channels,
adenosine, and atrial naturetic peptide, also play a role.6–9
At birth, the DA constricts in response to the acute increase
in oxygen (O2) tension coupled with a loss of vasodilators.
O2 may act through several different pathways to exert its
contractile effects on the DA,4 including cytochrome P450-
mediated induction of endothelin 110 and reactive oxygen
species-inhibition of voltage-gated potassium (Kþ) channels
(Kv1.5 and Kv2.1).11 O2 may also inhibit ATP-sensitive K
þ
(KATP) channels, resulting in membrane depolarization, acti-
vation of voltage dependent Ca2þ channels and increased
intracellular Ca2þ accumulation.12
Current therapies
There are few pharmacology-based tools currently available
for modulating DA tone.13–15 Introduced as a PDA therapy in
the mid-1970s,16–18 the nonsteroidal anti-inflammatory drug
(NSAID), indomethacin, facilitates DA closure by inhibiting
cyclooxygenase COX-1 (PTGS1) and COX-2 (PTGS2) enzymes
that are required for PGE2 synthesis. A potent vasoconstrictor,
indomethacin became the PDA drug of choice for many years,
despite its association with renal dysfunction, platelet abnor-
malities, spontaneous intestinal perforation, and NEC.19–21 In
the mid-1990s, ibuprofen emerged as an alternative to indo-
methacin, demonstrating equal efficacy, but with a decreased
risk of NEC.22–24 However, use of either of these non-selective
NSAIDs is still not ideal given their propensity to induce
generalized vasoconstriction.20,21,25 In addition, indometha-
cin and ibuprofen are ineffective in approximately 30% of
patients,26 exposing such infants to increased risk of renal
dysfunction, spontaneous intestinal perforation, and NEC
with no therapeutic benefit. Recently, acetaminophen has
been touted as the optimal choice for PDA management,
because it is less likely to cause peripheral vasoconstriction
and can be administered to infants with contraindications to
NSAIDs.27 Like the others, acetaminophen is a COX inhibitor,
although it may not be as effective at blocking PGE2 synthesis
in immature vessels, potentially limiting its effectiveness in
premature infants.28
The ability of PGE1 and PGE2 to relax the ex vivo fetal lamb
DA, first demonstrated in 1973 by Coceani and Olley,29 led to
initiation of several clinical trials to evaluate the efficacy of
PGE1 in maintenance of DA patency in infants with ductus-
dependent congenital heart defects.30–32 Today, PGE1 is still
the only pharmacology-based therapy used to keep the DA
open, despite its association with peripheral vasodilation,
apnea, fever, and other physiologic disruptions.13 Prolonged
treatment produces even more severe side effects, including
cortical hyperostosis, gastric-outlet obstruction, and pseudo-
Bartter syndrome.33 In addition, while PDA therapies can be
administered orally or intravenously, PGE1-mediated DA
dilation requires continuous intravenous infusion, another
significant limitation. Despite the inefficient nature of these
current tools, relatively little effort has been expended over
the last four decades to identify novel targets for pharmacol-
ogy-based DA manipulation.
Towards specific DA-targeted therapies
Lack of progress towards novel DA drug development is not
entirely unexpected given the low probability of success for
drug development programs in general. A recent study,34 the
largest of its kind, reports that from 2005–2015 only 8.5 % of
all industry-sponsored drug development programs ended
in FDA approval. Moreover, the rate at which new drugs are
validated and brought to market is staggeringly slow, with
the average drug spending 8.14 years in clinical trials.34
However, drugs with the highest likelihood of success target
proteins with these key characteristics: druggability, enrich-
ment in the tissue of interest, and demonstrated relevance to
disease35,36 (Fig. 1). Targets with some precedent for binding a
drug-like molecule are considered part of the “druggable
genome”.37 Most modern drugs act on receptors, enzymes,
and ion channels/transporters. However, as the pharmaceut-
ical industry devises new ways to target moieties such as
protein–protein interactions and nucleic acids, the druggable
genome will expand to include non-traditional targets.
Accordingly, there will be room for expansion of the potential
targets for DA therapy, beyond the PGE-pathway.
Traditional and non-traditional potential DA drug target
candidates listed in Table 1, include novel targets identified
as enriched in the DA, using array and RNA-seq analyses to
identify the DA’s unique transcriptional identity (reviewed by
Yarboro et al., this issue).38–48 In the majority of these studies,
the DA was compared to the ascending aorta, a natural choice
given their close proximity and the shared neural crest origin
of each vessel’s smooth muscle cells.49 While these analyses
are helpful, looking at DA-specific targets should be expanded
to include a comparison to renal, mesenteric, and cerebral
vessels, given the potential that novel drugs could, as do all
current DA drugs, have adverse effects on these vascular
Fig. 1 – Characteristics of ideal drug targets. DA drug targets
with the highest likelihood of receiving FDA approval are
those that are druggable, enriched in the DA, and have an
established link to PDA (denoted by asterisk in the central,
overlapping region of the diagram).
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Table 1 – Candidate DA drug targets. Representative list of potential DA drug targets. Candidates are classified as
traditional (receptor, enzyme, ion channel or transporter) or non-traditional drug targets and are organized by protein
category and type of evidence linking them to PDA (mouse model, human syndrome, or non-syndromic SNP).
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S E M I N A R S I N P E R I N A T O L O G Y 4 2 ( 2 0 1 8 ) 2 2 1 – 2 2 7 223
beds.50 While it is unlikely that any candidate will be
exclusively expressed in the DA, those that are significantly
enriched lend themselves to the possibility of targeting them
with a relatively low “Goldilocks” dose of drug—one that
would have just the right effect on the DA, but would be
insufficient to act on other tissues given low expression of the
target in those tissues.26
Additionally, several transcriptome studies analyzed
changes in gene expression in preterm vs term-gestation
vessels. This is important to consider given that PDA most
often occurs in the setting of prematurity and that immature
DAs are less responsive to indomethacin and often lack the
smooth muscle machinery to maintain DA closure even if
initial constriction is achieved.51 Therefore, targeting path-
ways involved in fetal DA maturation may be key to devel-
oping therapies with a higher success rate in preterm infants.
For instance, fetal DAs are significantly less responsive to
oxygen-induced constriction than term-gestation vessels.52–54
Therefore, novel PDA therapies that can compensate for a
diminished response to O2 by promoting endothelin signaling
or blocking Kþ channels might be more effective at closing
premature vessels.
Insights from animal studies
Animal models of PDA have been informative regarding
disease pathways that could be therapeutically targeted.4,55
Interestingly, PDA is the most common cardiac anomaly in
dogs. Studies show a sex-linked genetic predisposition, with
certain breeds and female dogs being at higher risk.55–57 A
similar sex-linked predisposition has been reported in
humans58 although this is not supported by more recent
analyses.59 Similarly, Brown Norway rats have a high preva-
lence of PDA, making them a popular experimental tool for
identifying gene alterations in the setting of disease.45
Finally, mouse models of PDA highlight the role of specific
genes in DA development and function. Some of the latter
have impaired smooth muscle development (Tfap2b−/−,
Myocd−/−, Myh1−/−), while others have impaired prostaglandin
signaling (Ptgs1/2−/−, Ptger4−/−, Slco2a1−/−, Hpdg−/−), which may
seem counterintuitive given the primary role of PGE2 in DA
dilation. However, these animals suggest an additional role
for prostaglandin signaling in maturing the contractile pro-
gram of the ductus.60 Still other animal models lack various
genes that are key in development pathways, including Notch
(Notch2/3−/−, Jag1−/−), BMP (BMP9/10−/−), chromatin remodel-
ing (Brg1−/−), platelet homeostasis (Nfe2−/−, Itga2b−/−), or
elastin and collagen crosslinking (Lox−/−).61 These animals
not only give molecular insight into disease-causing mecha-
nisms, they also provide established in vivo platforms for pre-
clinical validation of second-generation PDA drugs.
Insights from human studies
Results of animal studies are not always faithful predictors of
patient outcomes,62 highlighting the need for human genetic
studies.63 A representative set of the more than 100 single-
gene mutation syndromes featuring PDA that have now been
identified55,64,65 is listed in Table 1. Many of these syndromes
also feature complicated congenital heart defects, making it
difficult to parse out whether PDA is a primary lesion or the
result of other structural and hemodynamic anomalies.
Therefore, identifying gene variants associated with
non-syndromic PDA may be more informative for sporadi-
cally occurring PDA, which makes up the vast majority (90%)
of all PDA cases.66 Single nucleotide polymorphisms (SNPs)
associated with PDA26 or response to indomethacin67 have
also been reported (Table 1), although it has been difficult to
confirm these findings in replication cohorts.68,69
Proof of concept
Interestingly, targets of current PDA therapeutics fulfill all
three of the key characteristics of successful drug targets
illustrated in Figure 1. Indomethacin, ibuprofen, and acet-
aminophen all inhibit COX enzymes encoded by PTGS1 and
PTGS2 genes. These enzymes catalyze PGE2 synthesis, which
subsequently regulates DA tone by binding to the DA-
enriched receptor, PTGER4. Mice lacking these enzymes or
the receptor have a lethal PDA phenotype,44,70–73 demonstrat-
ing relevance of these targets to this disease. Therefore, it
may be reasonable to assume that novel DA drug targets with
the best chance of having clinical success will conform to a
similar pattern. As one example, KATP channels possess all
three key characteristics listed above. These channels are
hetero-octameric complexes of pore-forming inward rectifier
Kþ channel subunits (Kir6.1 or Kir6.2) and regulatory sulfo-
nylurea receptor subunits (SUR1, SUR2A, or SUR2B). Channel
isoforms have distinct pharmacological and physiological
characteristics and are expressed in a tissue-specific manner
(Table 2), making them potentially ideal targets for DA-
selective therapies.74
A regulatory link between KATP channels and DA tone is
becoming increasingly apparent. Vascular KATP channels,
formed of the Kir6.1/SUR2B isoform combination, are devel-
opmentally regulated and significantly enriched in the DA
compared to other vessels.38–42,45,48 Animal studies have
shown that the DA constricts in response to glibencla-
mide,12,75 a non-specific KATP channel inhibitor commonly
used to treat diabetes. Conversely, fetal or neonatal exposure
to diazoxide, a KATP channel activator, inhibited DA constric-
tion in rats,76 and was reported to cause DA reopening in
hypoglycemic infants.77 Most notably, 50% of patients with
Cantu syndrome, caused by activating mutations in Kir6.1 or
SUR2B, have a clinically significant PDA that is often resistant
Table 2 – Isoform-specific expression of KATP channel
subunits.
Subunits Tissue
Kir6.1/SUR2B Vascular smooth muscle and endothelium
KIR6.1/SUR2B Visceral smooth muscle
Kir6.2/SUR2A Skeletal muscle
Kir6.1/SUR2 Cardiac conduction system
Kir6.2/SUR1,2 Cardiomyocytes
Kir6.2/SUR1 Pancreatic β cells, brain
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to indomethacin therapy, thus requiring surgical ligation to
achieve closure.78
Capitalizing on the druggability and therapeutic potential
of KATP channels, several groups, including our own,
are working to develop subunit-specific activators and
inhibitors.79,80 Using a thallium flux-based high-throughput
screen, we identified a very potent novel KATP channel
agonist (VU063), with preferential activity towards the
pancreatic/neuronal channel isoform (Kir6.2/SUR1).74,79
We performed pressure myography assays on mouse DAs
as previously described41,81 to test the specificity and
vasoactive potential of this compound (Fig. 2). As expected,
the SUR2-preferring KATP channel activator, pinacidil, dilated
the DA in a dose-dependent manner, but VU063 had no effect
on DA tone. Thus, while VU063 would, just like diazoxide, be
conducive for treating hyperinsulinemia, unlike diazoxide it
would not induce off-target vascular effects. Along these
lines, it is likely that future studies will identify small
molecule antagonists/agonists that preferentially target the
vascular channel isoform (Kir6.1/SUR2B), which will allow for
a more specific way to modulate DA tone.
Perspective and prospects
In the 45 years since the first reports of indomethacin-
induced DA closure,16–18,29,82,83 relatively little headway has
been made in developing novel approaches for therapeutic
modulation of DA tone. As a consequence, there has been
little progress in establishing a standard of care over the
subsequent decades, leading to significant variability in treat-
ment strategies amongst neonatal care centers and even
between providers in a single care center.84,85 As we learn
more about the DA, it is becoming clear that PDA is a
deceptively complex condition that will likely benefit more
from personalized medicine rather than a one-pathway-fits all
approach to therapeutics. In lieu of redundant retrospective
case analyses, a greater emphasis should be placed on
multidisciplinary efforts to identify DA-modulating pathways
outside of the prostaglandin signaling cascade and to develop
specific pharmacological modifiers of those targets.
Moving towards this goal, increased access to human tissue
repositories86 coupled with the ability to perform large-scale
GWAS and other genome-wide studies will uncover new
PDA-associated genes. Furthermore, these studies will pro-
vide important pharmacogenetic information that could be
used at the bedside to prospectively determine the likelihood
of an individual patient responding to indomethacin, thereby
shielding non-responders from unnecessary exposure.87
Moreover, emerging technologies including the generation
of tissue-engineered ductus vessels88 and the creation of
immortalized human DA cell lines for use in high-throughput
small molecule screens will provide novel tools to identify
and validate second generation DA drugs, setting the
stage for rapid advances towards novel DA therapeutic
development.
Disclosures
We have no conflicts of interest to report.
r e f e r e n c e s
1. Rudolph AM. Fetal and neonatal pulmonary circulation. Annu
Rev Physiol. 1979;41:383–395.
2. Koch J, Hensley G, Roy L, Brown S, Ramaciotti C, Rosenfeld CR.
Prevalence of spontaneous closure of the ductus arteriosus in
neonates at a birth weight of 1000 grams or less. Pediatrics.
2006;117(4):1113–1121.
3. Dice JE, Bhatia J. Patent ductus arteriosus: an overview.
J Pediatr Pharmacol Ther. 2007;12(3):138–146.
4. Stoller JZ, Demauro SB, Dagle JM, Reese J. Current perspectives
on pathobiology of the ductus arteriosus. J Clin Exp Cardiol.
2012;8(1).
5. Schneider M, Zartner P, Sidiropoulos A, Konertz W, Hausdorf G.
Stent implantation of the arterial duct in newborns with duct-
dependent circulation. Eur Heart J. 1998;19(9):1401–1409.
6. Akaike T, Minamisawa S. Role of ion channels in ductus
arteriosus closure. Hum Genet Embryol. 2014(3):3.
7. Mentzer RM Jr., Ely SW, Lasley RD, Mainwaring RD, Wright EM Jr.,
Berne RM. Hormonal role of adenosine in maintaining patency of
the ductus arteriosus in fetal lambs. Ann Surg. 1985;202(2):
223–230.
8. Toyoshima K, Momma K, Imamura S, Nakanishi T. In vivo
dilatation of the postnatal ductus arteriosus by atrial natriu-
retic peptide in the rat. Neonatology. 2007;92(2):139–144.
9. Andersson S, Tikkanen I, Pesonen E, Meretoja O, Hynynen M,
Fyhrquist F. Atrial natriuretic peptide in patent ductus arte-
riosus. Pediatr Res. 1987;21(4):396–398.
10. Coceani F, Kelsey L, Seidlitz E, Korzekwa K. Inhibition of the
contraction of the ductus arteriosus to oxygen by 1-amino-
benzotriazole, a mechanism-based inactivator of cytochrome
P450. Br J Pharmacol. 1996;117(7):1586–1592.
11. Michelakis ED, Rebeyka I, Wu X, et al. O2 sensing in the
human ductus arteriosus: regulation of voltage-gated Kþ
channels in smooth muscle cells by a mitochondrial redox
sensor. Circ Res. 2002;91(6):478–486.
12. Waleh N, Reese J, Kajino H, et al. Oxygen-induced tension in
the sheep ductus arteriosus: effects of gestation on potassium
and calcium channel regulation. Pediatr Res. 2009;65(3):
285–290.
13. Lewis AB, Freed MD, Heymann MA, Roehl SL, Kensey RC. Side
effects of therapy with prostaglandin E1 in infants with
Fig. 2 – Isolated mouse DAs were mounted in microvessel
perfusion chambers for use in pressure myography assays.
Vessels were treated with increasing concentrations of
pinacidil or VU063. Changes in lumen diameter were
measured and plotted as a percent change from the initial
lumen diameter reading under baseline (bl) conditions.
Pinacidil dilated the DA, while VU063 had no effect.
S E M I N A R S I N P E R I N A T O L O G Y 4 2 ( 2 0 1 8 ) 2 2 1 – 2 2 7 225
critical congenital heart disease. Circulation. 1981;64(5):
893–898.
14. Coceani F. Therapeutic manipulation of the ductus arteriosus:
current options and future prospects. Pol Arch Med Wewn.
2014;124(1-2):58–64.
15. Olley PM, Coceani F. Prostaglandins and the ductus arterio-
sus. Annu Rev Med. 1981;32:375–385.
16. Coceani F, Olley PM, Bodach E. Lamb ductus arteriosus: effect
of prostaglandin synthesis inhibitors on the muscle tone and
the response to prostaglandin E2. Prostaglandins. 1975;9(2):
299–308.
17. Friedman WF, Hirschklau MJ, Printz MP, Pitlick PT, Kirkpatrick
SE. Pharmacologic closure of patent ductus arteriosus in the
premature infant. N Engl J Med. 1976;295(10):526–529.
18. Heymann MA, Rudolph AM, Silverman NH. Closure of the
ductus arteriosus in premature infants by inhibition of
prostaglandin synthesis. N Engl J Med. 1976;295(10):530–533.
19. Mehta S, Younoszai A, Pietz J, Achanti B. Pharmacological
closure of the patent ductus arteriosus. Images Paediatr Cardiol.
2003;5(1):1–15.
20. Christmann V, Liem KD, Semmekrot BA, van de Bor M.
Changes in cerebral, renal and mesenteric blood flow velocity
during continuous and bolus infusion of indomethacin. Acta
Paediatr. 2002;91(4):440–446.
21. Norton ME, Merrill J, Cooper BA, Kuller JA, Clyman RI. Neo-
natal complications after the administration of indomethacin
for preterm labor. N Engl J Med. 1993;329(22):1602–1607.
22. Thomas RL, Parker GC, Van Overmeire B, Aranda JV. A meta-
analysis of ibuprofen versus indomethacin for closure of
patent ductus arteriosus. Eur J Pediatr. 2005;164(3):135–140.
23. Van Overmeire B, Follens I, Hartmann S, Creten WL, Van
Acker KJ. Treatment of patent ductus arteriosus with ibupro-
fen. Arch Dis Child Fetal Neonatal Ed. 1997;76(3):F179–184.
24. Van Overmeire B, Smets K, Lecoutere D, et al. A comparison of
ibuprofen and indomethacin for closure of patent ductus
arteriosus. N Engl J Med. 2000;343(10):674–681.
25. Reese J, Shelton EL, Slaughter JC, McNamara PJ. Prophylactic
indomethacin revisited. J Pediatr. 2017;186:11–14 e11.
26. Lewis TR, Shelton EL, Van Driest SL, Kannankeril PJ, Reese J.
Genetics of the patent ductus arteriosus (PDA) and pharma-
cogenetics of PDA treatment. Semin Fetal Neonatal Med. 2018
[Epub ahead of print].
27. Hammerman C, Bin-Nun A, Markovitch E, Schimmel MS,
Kaplan M, Fink D. Ductal closure with paracetamol: a surpris-
ing new approach to patent ductus arteriosus treatment.
Pediatrics. 2011;128(6):e1618–1621.
28. El-Khuffash A, Jain A, Corcoran D, et al. Efficacy of para-
cetamol on patent ductus arteriosus closure may be dose
dependent: evidence from human and murine studies. Pediatr
Res. 2014;76(3):238–244.
29. Coceani F, Olley PM. The response of the ductus arteriosus to
prostaglandins. Can J Physiol Pharmacol. 1973;51(3):220–225.
30. Elliott RB, Starling MB, Neutze JM. Medical manipulation of
the ductus arteriosus. Lancet. 1975;1(7899):140–142.
31. Freed MD, Heymann MA, Lewis AB, Roehl SL, Kensey RC.
Prostaglandin E1 infants with ductus arteriosus-dependent
congenital heart disease. Circulation. 1981;64(5):899–905.
32. Olley PM, Coceani F, Bodach E. E-type prostaglandins: a new
emergency therapy for certain cyanotic congenital heart
malformations. Circulation. 1976;53(4):728–731.
33. Talosi G, Katona M, Turi S. Side-effects of long-term prostaglan-
din E(1) treatment in neonates. Pediatr Int. 2007;49(3):335–340.
34. Wong CH, Siah KW, Lo AW. Estimation of clinical trial success
rates and related parameters. Biostatistics 2018. [Epub ahead
of print].
35. Finan C, Gaulton A, Kruger FA, et al. The druggable genome
and support for target identification and validation in drug
development. Sci Transl Med. 2017(383):9.
36. Gashaw I, Ellinghaus P, Sommer A, Asadullah K. What
makes a good drug target? Drug Discov Today. 2011;
16(23-24):1037–1043.
37. Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug
Discov. 2002;1(9):727–730.
38. Bokenkamp R, van Brempt R, van Munsteren JC, et al. Dlx1
and Rgs5 in the ductus arteriosus: vessel-specific genes
identified by transcriptional profiling of laser-capture micro-
dissected endothelial and smooth muscle cells. PLoS One.
2014;9(1):e86892.
39. Costa M, Barogi S, Socci ND, et al. Gene expression in ductus
arteriosus and aorta: comparison of birth and oxygen effects.
Physiol Genomics. 2006;25(2):250–262.
40. Jin MH, Yokoyama U, Sato Y, et al. DNA microarray profiling
identified a new role of growth hormone in vascular remod-
eling of rat ductus arteriosus. J Physiol Sci. 2011;61(3):167–179.
41. Shelton EL, Ector G, Galindo CL, et al. Transcriptional profiling
reveals ductus arteriosus-specific genes that regulate vascu-
lar tone. Physiol Genomics. 2014;46(13):457–466.
42. Yokoyama U, Sato Y, Akaike T, et al. Maternal vitamin A
alters gene profiles and structural maturation of the rat
ductus arteriosus. Physiol Genomics. 2007;31(1):139–157.
43. Goyal R, Goyal D, Longo LD, Clyman RI. Microarray gene
expression analysis in ovine ductus arteriosus during fetal
development and birth transition. Pediatr Res. 2016;80
(4):610–618.
44. Gruzdev A, Nguyen M, Kovarova M, Koller BH. PGE2
through the EP4 receptor controls smooth muscle gene
expression patterns in the ductus arteriosus critical for
remodeling at birth. Prostaglandins Other Lipid Mediat. 2012;97
(3-4):109–119.
45. Hsieh YT, Liu NM, Ohmori E, et al. Transcription profiles of
the ductus arteriosus in Brown-Norway rats with irregular
elastic fiber formation. Circ J. 2014;78(5):1224–1233.
46. Mueller PP, Drynda A, Goltz D, Hoehn R, Hauser H, Peuster M.
Common signatures for gene expression in postnatal patients
with patent arterial ducts and stented arteries. Cardiol Young.
2009;19(4):352–359.
47. Parikh P, Bai H, Swartz MF, Alfieris GM, Dean DA. Identifica-
tion of differentially regulated genes in human patent ductus
arteriosus. Exp Biol Med. 2016;241(18):2112–2118.
48. Waleh N, Barrette AM, Dagle JM, et al. Effects of advancing
gestation and non-caucasian race on ductus arteriosus gene
expression. J Pediatr. 2015;167(5):1033–1041.
49. Pfaltzgraff ER, Shelton EL, Galindo CL, et al. Embryonic
domains of the aorta derived from diverse origins exhibit
distinct properties that converge into a common phenotype
in the adult. J Mol Cell Cardiol. 2014;69:88–96.
50. Clyman RI, Couto J, Murphy GM. Patent ductus arteriosus: are
current neonatal treatment options better or worse than no
treatment at all? Semin Perinatol. 2012;36(2):123–129.
51. Quinn D, Cooper B, Clyman RI. Factors associated with
permanent closure of the ductus arteriosus: a role for
prolonged indomethacin therapy. Pediatrics. 2002;110(1 Pt 1):
e10.
52. Dunn PM, Speidel BD. Use of oxygen to close patent ductus
arteriosus in preterm infants. Lancet. 1973;2(7824):333–334.
53. Noel S, Cassin S. Maturation of contractile response of
ductus arteriosus to oxygen and drugs. Am J Physiol. 1976;
231(1):240–243.
54. Reese J, O’Mara PW, Poole SD, et al. Regulation of the fetal
mouse ductus arteriosus is dependent on interaction of nitric
oxide and COX enzymes in the ductal wall. Prostaglandins
Other Lipid Mediat. 2009;88(3-4):89–96.
55. Bokenkamp R, DeRuiter MC, van Munsteren C, Gittenberger-
de Groot AC. Insights into the pathogenesis and genetic
background of patency of the ductus arteriosus. Neonatology.
2010;98(1):6–17.
S E M I N A R S I N P E R I N A T O L O G Y 4 2 ( 2 0 1 8 ) 2 2 1 – 2 2 7226
56. Patterson DF, Pyle RL, Buchanan JW, Trautvetter E, Abt DA.
Hereditary patent ductus arteriosus and its sequelae in the
dog. Circ Res. 1971;29(1):1–13.
57. Broaddus K, Tillson M. Patent ductus arteriosus in dogs.
Compend Contin Educ Vet. 2010;32(9):E3.
58. Schneider DJ. The patent ductus arteriosus in term infants,
children, and adults. Semin Perinatol. 2012;36(2):146–153.
59. Tripathi A, Black GB, Park YM, Jerrell JM. Prevalence and
management of patent ductus arteriosus in a pediatric
medicaid cohort. Clin Cardiol. 2013;36(9):502–506.
60. Reese J, Waleh N, Poole SD, Brown N, Roman C, Clyman RI.
Chronic in utero cyclooxygenase inhibition alters PGE2-regu-
lated ductus arteriosus contractile pathways and prevents
postnatal closure. Pediatr Res. 2009;66(2):155–161.
61. Staiculescu MC, Kim J, Mecham RP, Wagenseil JE. Mechanical
behavior andmatrisome gene expression in the aneurysm-prone
thoracic aorta of newborn lysyl oxidase knockout mice. Am J
Physiol Heart Circ Physiol. 2017;313(2):H446–H456.
62. Bracken MB. Why animal studies are often poor predictors of
human reactions to exposure. J R Soc Med. 2009;102(3):120–122.
63. Plenge RM, Scolnick EM, Altshuler D. Validating therapeutic
targets through human genetics. Nat Rev Drug Discov. 2013;12
(8):581–594.
64. Hajj H, Dagle JM. Genetics of patent ductus arteriosus sus-
ceptibility and treatment. Semin Perinatol. 2012;36(2):98–104.
65. Patel PM, Momany AM, Schaa KL, et al. Genetic modifiers of
patent ductus arteriosus in term infants. J Pediatr. 2016;176:
57–61 e51.
66. Mani A, Meraji SM, Houshyar R, et al. Finding genetic
contributions to sporadic disease: a recessive locus at 12q24
commonly contributes to patent ductus arteriosus. Proc Natl
Acad Sci U S A. 2002;99(23):15054–15059.
67. Smith CJ, Ryckman KK, Bahr TM, Dagle JM. Polymorphisms in
CYP2C9 are associated with response to indomethacin among
neonates with patent ductus arteriosus. Pediatr Res. 2017;82(5):
776–780.
68. Kawase K, Sugiura T, Nagaya Y, et al. Single nucleotide
polymorphisms in AGTR1, TFAP2B, and TRAF1 are not asso-
ciated with the incidence of patent ductus arteriosus in
Japanese preterm infants. Pediatr Int. 2016;58(6):461–466.
69. Dagle JM, Lepp NT, Cooper ME, et al. Determination of genetic
predisposition to patent ductus arteriosus in preterm infants.
Pediatrics. 2009;123(4):1116–1123.
70. Loftin CD, Trivedi DB, Tiano HF, et al. Failure of ductus
arteriosus closure and remodeling in neonatal mice deficient
in cyclooxygenase-1 and cyclooxygenase-2. Proc Natl Acad Sci
U S A. 2001;98(3):1059–1064.
71. Reese J, Anderson JD, Brown N, Roman C, Clyman RI. Inhib-
ition of cyclooxygenase isoforms in late—but not midgesta-
tion decreases contractility of the ductus arteriosus and
prevents postnatal closure in mice. Am J Physiol Regul Integr
Comp Physiol. 2006;291(6):R1717–1723.
72. Reese J, Paria BC, Brown N, Zhao X, Morrow JD, Dey SK.
Coordinated regulation of fetal and maternal prostaglandins
directs successful birth and postnatal adaptation in the
mouse. Proc Natl Acad Sci U S A. 2000;97(17):9759–9764.
73. Segi E, Sugimoto Y, Yamasaki A, et al. Patent ductus arterio-
sus and neonatal death in prostaglandin receptor EP4-defi-
cient mice. Biochem Biophys Res Commun. 1998;246(1):7–12.
74. Kharade SV, Nichols C, Denton JS. The shifting landscape of
KATP channelopathies and the need for ‘sharper’ therapeu-
tics. Future Med Chem. 2016;8(7):789–802.
75. Nakanishi T, Gu H, Hagiwara N, Momma K. Mechanisms of
oxygen-induced contraction of ductus arteriosus isolated
from the fetal rabbit. Circ Res. 1993;72(2):1218–1228.
76. Toyoshima K, Momma K, Ishii T, Nakanishi T. Dilatation of
the ductus arteriosus by diazoxide in fetal and neonatal rats.
Pediatr Int. 2017;59(12):1246–1251.
77. Demirel F, Unal S, Cetin II, Esen I, Arasli A. Pulmonary
hypertension and reopening of the ductus arteriosus in an
infant treated with diazoxide. J Pediatr Endocrinol Metab.
2011;24(7-8):603–605.
78. Grange DK, Nichols CG, Singh GK. Cantu Syndrome and
related disorders. In: Adam MP, Ardinger HH, Pagon RA,
et al., eds. GeneReviews. Seattle, WA, 1993.
79. Raphemot R, Swale DR, Dadi PK, et al. Direct activation of
beta-cell KATP channels with a novel xanthine derivative.Mol
Pharmacol. 2014;85(6):858–865.
80. Dabrowski M, Ashcroft FM, Ashfield R, et al. The novel
diazoxide analog 3-isopropylamino-7-methoxy-4H-1,2,4-ben-
zothiadiazine 1,1-dioxide is a selective Kir6.2/SUR1 channel
opener. Diabetes. 2002;51(6):1896–1906.
81. Hooper CW, Delaney C, Streeter T, et al. Selective serotonin
reuptake inhibitor exposure constricts the mouse ductus
arteriosus in utero. Am J Physiol Heart Circ Physiol. 2016;311
(3):H572–581.
82. Starling MB, Elliott RB. The effects of prostaglandins, prosta-
glandin inhibitors, and oxygen on the closure of the ductus
arteriosus, pulmonary arteries and umbilical vessels in vitro.
Prostaglandins. 1974;8(3):187–203.
83. Sharpe GL, Thalme B, Larsson KS. Studies on closure of the
ductus arteriosus. XI. Ductal closure in utero by a prostaglan-
din synthetase inhibitor. Prostaglandins. 1974;8(5):363–368.
84. Laughon M, Bose C, Clark R. Treatment strategies to prevent
or close a patent ductus arteriosus in preterm infants and
outcomes. J Perinatol. 2007;27(3):164–170.
85. Bose CL, Laughon MM. Patent ductus arteriosus: lack of
evidence for common treatments. Arch Dis Child Fetal Neonatal
Ed. 2007;92(6):F498–502.
86. McGregor TL, Van Driest SL, Brothers KB, Bowton EA, Muglia
LJ, Roden DM. Inclusion of pediatric samples in an opt-out
biorepository linking DNA to de-identified medical records:
pediatric BioVU. Clin Pharmacol Ther. 2013;93(2):204–211.
87. Carlson B. Vanderbilt pioneers bedside genetics. Biotechnol
Healthc. 2012;9(2):31–32.
88. Saito J, Yokoyama U, Nicho N, et al. Tissue-type plasminogen
activator contributes to remodeling of the rat ductus arterio-
sus. PLoS One. 2018;13(1):e0190871.
S E M I N A R S I N P E R I N A T O L O G Y 4 2 ( 2 0 1 8 ) 2 2 1 – 2 2 7 227
